Limited utility of rapamycin in severe, refractory Wegener's granulomatosis

Journal of Rheumatology

Volumn 36, Issue 1, 2009, Pages 116-119

  Koening, Curry L ^a,f   Hernández Rodríguez, José ^b   Molloy, Eamonn S ^c   Clark, Tiffany M ^c   Hoffman, Gary S ^d,e  

^a UNIVERSITY OF UTAH   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^e Department of Rheumatic and Immunologic Diseases ^*  (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Sirolimus; Wegener's granulomatosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; MALE; MOUTH PAIN; NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIROLIMUS; TREATMENT FAILURE; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 58149526651     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.080664     Document Type: Article

References (15)

1. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996;39:87-92.
2. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958;2:265-70.
3. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: Induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999;42:2666-73.
4. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
5. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
6. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
7. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
8. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35 Suppl:7-14.
9. Morice WG, Wiederrecht G, Brunn GJ, Siekierka JJ, Abraham RT. Rapamycin inhibition of interleukin-2-dependent p33cdk2 and p34cdc2 kinase activation in T lymphocytes. J Biol Chem 1993;268:22737-45.
10. Champion L, Stern M, Israel-Biet D, et al. Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006;144:505-9.
11. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007;83:883-92.
12. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004;110:2694-700.
13. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol 1999;103:885-94.
14. Stegeman CA, Tervaert JW, Huitema MG, Kallenberg CG. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol 1993;91:415-20.
15. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.